Noxopharm announces first Covid-19 patient treated in Veyonda study

This article was originally published here

NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care

The post Noxopharm announces first Covid-19 patient treated in Veyonda study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply